RxDoctor Payments DataLook up a doctor →

Ahmed Abdelaziz, MD

Hematology & Oncology · Tucson, AZNPI 1477817971

Payments from drug & device makers

$962,336in general payments, 2019–2025

Across 605 payments — averaging $1590.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$362K
  • AstraZeneca$262K
  • Amgen$212K
  • Genentech, Inc.$107K
  • TG Therapeutics, Inc.$7K
  • Medtronic$3K
  • plus $9K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
E.r. Squibb & Sons, L.L.C.34$361,655
AstraZeneca(2 entities)36$262,473
Amgen27$212,086
Genentech, Inc.20$106,665
TG Therapeutics, Inc.5$6,520
Medtronic17$3,418
Pfizer72$1,041
Novartis51$929
Janssen Research & Development, LLC1$926
Bristol Myers Squibb44$694
Genentech USA, Inc.26$505
Gilead(2 entities)23$446
Johnson & Johnson(2 entities)15$300
Merck23$284
Genmab U.S., Inc.12$270
Daiichi Sankyo Inc.11$249
Sanofi10$249
AbbVie11$246
Sumitomo Pharma America, Inc.10$233
GSK12$227
Regeneron Healthcare Solutions, Inc.8$194
Intuitive Surgical1$192
Array Biopharma Inc11$173
Incyte Corporation8$160
Exelixis Inc.7$159
Bayer11$155
Boehringer Ingelheim7$133
Takeda Pharmaceuticals U.S.A., Inc.6$129
Blueprint Medicines Corporation5$111
Eisai Inc.5$108
Rigel Pharmaceuticals, Inc.6$84
Seagen Inc.5$81
EMD Serono, Inc.5$80
CTI Biopharma Corp.3$75
Lilly USA, LLC5$71
Ipsen Biopharmaceuticals, Inc4$70
Mirati Therapeutics, Inc.4$63
Pharmacosmos Therapeutics Inc.3$62
Stemline Therapeutics Inc.3$61
Tersera Therapeutics LLC2$60
Pharmacyclics LLC, An Abbvie Company3$58
Beigene USA, Inc.3$55
Sun Pharmaceutical Industries Inc.2$47
Pharmaessentia USA Corporation2$47
Springworks Therapeutics, Inc.2$41
Morphosys, US Inc.2$33
Lexicon Pharmaceuticals, Inc.2$32
Dendreon Pharmaceuticals LLC1$31
Cardinal Health 414 LLC1$29
Caris MPI, Inc.1$29
Adaptive Biotechnologies Corporation2$29
Alnylam Pharmaceuticals Inc.1$23
Boston Scientific1$23
Spectrum Pharmaceuticals Inc.1$21
Kyowa Kirin, Inc.1$21
Taiho Oncology, Inc.1$20
Deciphera Pharmaceuticals Inc.1$20
Apellis Pharmaceuticals, Inc.1$17
EUSA Pharma (US) LLC1$17
Astellas Pharma US Inc1$17

How this compares

$962,336 in reported general payments places this provider in the 80th percentile of 261 hematology & oncology providers in Arizona.

See all hematology & oncology providers in Arizona

Medicare billing

Part B allowed, 2024
$2,933,295
Medicare patients
681
Services billed
241,352

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →